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Introduction
In recent years, a better molecular characterization of lung 
cancer resulted in relevant improvements in treatment 
planning and led to the creation of effective targeted 
therapies (1). In general, the term targeted therapy includes 
a wide range of different therapies, such as inhibitors of 
signal transduction, inhibitors of angiogenesis or modulators 
of the immune system (2). Despite non-small cell lung 
cancer (NSCLC) was initially considered not responsive 
to immune-mediated drugs because of failed attempts with 
interleukin-2, interferon or Bacillus of Calmette-Guerin (3), 
in the last years a great interest has arisen on new and 
promising immunomodulatory monoclonal antibodies. In 
fact, since 2015, three immune check-point inhibitors (ICIs) 
were approved by the US Food and Drug Administration 
(FDA) for the treatment of advanced NSCLC (4-6) and 
combinations of different immunomodulatory monoclonal 
antibodies are under investigation (7). The use of these 
drugs is spreading worldwide, they are now considered 
clinical practice standard in different settings and their use 
is expected to increase significantly in the near future (2). 
As treatment options for lung cancer advance and vary, 
the different patterns of radiological response increase in 
number and heterogeneity. Specifically, in consideration 
of their peculiar mechanism, ICIs can determine unusual 
response patterns (such as the pseudo-progression pattern) 
and adverse event profiles on imaging.
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The aim of this review is to describe the radiological 
findings after ICIs therapy, to discuss the specific response 
criteria [including immune-related response criteria (irRC), 
irRECIST and iRECIST] and the imaging of immune 
related adverse events.
Radiological response evaluation
WHO and RECIST 1.1
To evaluate the effectiveness of chemotherapy agents, 
radiologists have traditionally relied on response criteria, 
such as WHO and RECIST criteria.
WHO criteria were first proposed in 1981; the concept 
behind them was to evaluate the tumor burden as the 
sum of the products of the diameters. These criteria were 
often considered overly sensitive and one of the criticisms 
usually addressed to them is the fact that progressive disease 
(PD) could be easily diagnosed on the basis of minor 
changes in tumor size or even measurement errors (8). 
RECIST criteria were proposed in 2000 (and revised in 
2009, RECIST 1.1) by the WHO, the National Cancer 
Institute, and the European Organization for Research and 
Treatment of Cancer (EORTC). The RECIST criteria 
include definitions of minimum size of lesions and use of 
a measurement in only one dimension. According to these 
criteria, PD is defined as the appearance of new lesions or, 
at least, a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study 
(versus an increase of 25% or more according to the WHO 
criteria). These criteria have been widely used for the 
outcome evaluation in prospective studies and trials (9-11).
Morphological changes after immunotherapy
Relevantly, both these criteria (WHO and RECIST 1.1) 
assumed that an increase in size of the target lesion and/
or the appearance of new lesions denote a PD in patients 
treated with cytotoxic agents, which are subsequently 
discontinued once PD has been demonstrated. Indeed, these 
response criteria are optimized to evaluate the cytotoxic 
effects of conventional chemotherapeutic agents on tumors, 
where shrinkage of the lesion at the cross-sectional imaging 
is strictly related to a response to cytotoxic drugs (12,13).
Targeted therapies, especially immune-mediated drugs, 
may determine different patterns of radiological response, 
not correctly estimated with WHO and RECIST criteria. 
One of the most common and challenging condition for the 
morphological evaluation of the response is the so called 
“pseudo-progression”, a condition where the target lesion 
apparently continues to grow at the first cross sectional 
imaging (CSI) check (even with concomitant appearance 
of new lesions) and then remains stable, shrinks in size or 
disappears during the subsequent CSI controls. Proposed 
etiologies for these morphologic changes are two: (I) 
continuous tumor growth during the immune response 
mounting and/or (II) inflammation of the existing lesions 
and of other lesions initially not visible at CSI, due to 
hyper-activated T cells (13). Pseudo-progression has been 
reported for anti-PD-1, anti-PD-L1, and anti-CTLA-4 
agents not only in lung cancer but also in other cancers, 
such as melanoma, renal cell carcinoma, and bladder cancer 
(13-15). This response pattern can occur in the lymph 
nodes but is more commonly described in non-nodal 
sites (13,16).
Another interesting and atypical pattern of response 
after immunotherapy is the so-called dissociated response, 
defined as the concomitant decrease in certain tumoral 
elements and increase in other sites (Figure 1). According to 
literature series (17), the incidence of this response pattern 
is not negligible, and some organs may be more often 
involved [such as adrenal lesions (18)].
To correctly interpret the changes in morphology of 
the lesion under ICIs treatment, in 2004 and 2005 a panel 
of experts summed up in five statements the criticalities 
of these morphological changes of the tumor (1,3): (I) 
time needed to see anti-tumoral effect may be longer 
for immune therapies than for cytotoxic therapies; (II) 
responses to immune therapies can be demonstrated 
even after conventional PD; (III) to discontinue immune 
therapy cannot be appropriate in some cases, unless PD is 
confirmed (as is usually done for response); (IV) allowance 
for “clinically insignificant” PD (e.g., small new lesions in 
the presence of other responsive lesions) is recommended; 
and (V) maintained stable disease (SD) may represent 
presence of antitumor activity.
irRC
The diffuse awareness of these different radiological 
patterns, gained from the experience on the first melanoma 
trials, led to the proposal of the irRC (3). Based from an 
adaptation of WHO criteria, irRC differs significantly 
from RECIST 1.1. In fact, the number of lesion to 
evaluate is higher if compared to RECIST 1.1 (up to 5 per 
organ, up to 10 visceral vs. 2 per organ, 5 in total) and the 
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measurement is bidimensional instead of unidimensional. 
Relevantly, in irRC, new lesions are not considered PD but 
are incorporated in total tumor burden (Table 1). 
Despite these described advancements, several critiques 
were addressed to irRC criteria. First, the reproducibility 
of bidimensional assessment is lower if compared with 
unidimensional assessment; second, the large number 
of target lesions to be measured can be time consuming; 
third, lymph nodes assessment is not clearly evaluated 
(1,19). In addition, despite some literature data showing 
underestimation of the benefit of pembrolizumab in 15% of 
melanoma patients with RECIST 1.1 criteria if compared 
with irRC (16), data concerning ICIs and lung cancer 
patients are less clear: for instance, recent reports evaluating 
ICIs response in lung cancer patients suggested similar 
prognostic significance between irRC and RECIST 1.1 
criteria (20).
irRECIST
In order to obtain a more reproducible and faster reporting 
system, Nishino and Coll. proposed the irRECIST 
criteria (12), a system based on unidimensional evaluation 
and lower number of target lesions. irRECIST are very 
A B
C D
Figure 1 Pseudoprogression and dissociated response. A 68-year-old male patient with history of NSCLC metastatic to lung and liver. (A,B) 
Axial chest CT images before (A) and after 12 weeks (B) of treatment with nivolumab (an anti-PD-1 monoclonal antibody) showing increase 
in size of the lesions (arrows) and appearance of new lung nodules (circles: these findings were stable at the subsequent CSI); (C,D) axial 
CT images of the same patients before (C) and after 12 weeks (D) of treatment showing decrease in size of some liver lesions (arrows) and 
disappearance of a metastatic lesion (circle). NSCLC, non-small cell lung cancer; CSI, cross sectional imaging.
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similar to RECIST 1.1: in fact, they are similar in terms 
of criteria for selecting target (5 total target lesions with a 
maximum of 2 per organ) and non-target lesion, and how 
these lesions should be measured.
The main difference between irRECIST and RECIST 
1.1 is how new lesions are incorporated into the response 
assessment. In irRECIST, new lesions are incorporated in 
the total measured tumor burden (TMTB); differently from 
the RECIST 1.1, new lesions do not immediately mean PD. 
In irRECIST, new lesions should be defined as measurable 
or non-measurable, and those selected as new targets 
should meet the same criteria for inclusion as the baseline 
lesions. Thus, in case of new target lesions appearance, the 
longest diameters of existing non-nodal target plus new 
non-lymph node target lesions, and short-axis diameters 
of existing lymph node targets plus new lymph node target 
lesions constitute the TMTB. This method allows to do 
not discontinue a potentially effective therapy in case of 
appearance of new lesions.
The specific thresholds for irPR (partial response) 
and irPD are aligned with RECIST 1.1 (see Table 2). 
Confirmatory evaluation of PD is not mandatory; however, 
confirmation of progression should be recommended 
for patients with a minimal TMTB increase over 20%, 
particularly during the first 12 weeks of treatment (12,19).
iRECIST
Recently, the RECIST working group prospectively analyzed 
data from several clinical trials of immunotherapeutic 
agents (18), finding out a diffused use of RECIST 1.1 to 
define primary and secondary efficacy endpoints whereas 
irRC and irRECIST were used for exploratory/minor 
endpoints only (16,21). Critiques were also addressed 
to the substantial heterogeneity of the response criteria 
used in different clinical trials and subsequent potentially 
misleading interpretation of pooled datasets. The RECIST 
working group therefore came to propose the iRECIST 
criteria with the goal to provide a consistent and common 
language for the management of data deriving from 
Table 1 Comparison of irRC, irRECIST and iRECIST criteria
Criteria irRC irRECIST iRECIST
Definition of 
measurable disease
Selection of 5 lesions  
(≥5 × 5 mm) per organ (up to 10 
visceral and 5 cutaneous ones)
Selection of maximum 5 (2 
per organ) lesions (≥10 mm in 
diameter; ≥15 mm for nodal 
lesions)
Selection of maximum 5 (2 per organ) 
lesions (≥10 mm in diameter; ≥15 mm for 
nodal lesions)
New lesions are assessed as the 
baseline and added to TTB at 
follow-up
New lesions are included in the 
sum of target lesions to define 
the TMTB at follow-up
New lesions are recorded separately on the 
case report form (but not included in the 
sum of lesions for target lesions identified 
at baseline)
Method of 
measurement
Bidimensional  
(longest diameter × the longest 
perpendicular diameter)
Unidimensional (longest 
diameter)
Unidimensional (longest diameter)
Appearance of new 
lesions
Added to TTB; do not constitute 
PD automatically
Added to TMTB; do not 
constitute PD automatically
Result in iUPD
iCPD is assigned if at next CSI control 
additional new lesions appear or an increase 
in size of new lesions is seen (≥5 mm for 
sum of new target lesion or any increase in 
new non-target lesion)
The appearance of new lesions when none 
have previously been recorded can also 
confirm iCPD
irRC, immune-related response criteria; irRECIST, immune-related Response Evaluation Criteria in Solid Tumors; iRECIST, immune 
RECIST; TTB, total tumor burden; TMTB, total measured tumor burden; PD, progressive disease; iUPD, unconfirmed progressive disease; 
iCPD, confirmed progressive disease; CSI, cross-sectional imaging.
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different trials of immunotherapeutic agents (21).
iRECIST are comparable with RECIST 1.1 and 
irRECIST in terms of recommended imaging modalities, 
definitions of measurable lesions and target lesions (9,18). 
Notably, target and non-target lesions are not counted 
together and therefore not added to the greatest dimensions 
of all target lesions, in contrast to irRECIST (see Table 1).
The response categories of iRECIST include iCR 
Table 2 Comparison of irRC, irRECIST and iRECIST response assessment
Response assessment irRC irRECIST iRECIST
CR Complete disappearance of all lesions 
(whether measurable or not, and no new 
lesions)
Disappearance of all target 
and non-target lesions
Disappearance of all target and non-
target lesions
Confirmation by a repeat, consecutive CSI 
controls no less than 4 weeks from the date 
first documented
Nodal short axis  
diameter <10 mm
Nodal short axis diameter <10 mm
No new lesions No new lesions
Confirmation of response is 
not mandatory
PR Decrease in TTB ≥50% relative to baseline Decrease of ≥30% in tumour 
burden relative to baseline 
Decrease of ≥30% in tumour burden 
relative to baseline 
Confirmed by a consecutive CSI control at 
least 4 weeks after first documentation
Non-unequivocal progression 
of non-target lesions
Non-unequivocal progression of 
non-target lesions
No new lesions No new lesions
PD Increase in tumor burden ≥25% relative to 
nadir
≥20% increase and ≥5 mm 
absolute increase in TMTB 
compared to nadir (minimum 
recorded tumor burden)
iUPD: 
	Increase ≥20% of the sum of 
longest diameters compared 
with nadir (minimum 5 mm) 
or progression of non-target 
lesions or new lesion; 
	Confirmation is required minim 
4–8 weeks later the first iUPD 
assessment
Confirmation by a repeat, consecutive CSI 
control no less than 4 weeks from the date 
first documented
irPD for non-target or new 
non-measurable lesions
iCPD: 
 Increased size of target or non-
target lesions;
 Increase in the sum of new 
target lesions >5 mm; 
 Progression of the non-target 
lesions; 
 Appearance of another new 
lesion
Confirmation of progression 
is recommended minimum 
4 weeks after the first irPD 
evaluation
SD When neither PR nor PD can be established When neither PR nor PD can 
be established
When neither PR nor PD can be 
established
irRC, immune-related response criteria; irRECIST, immune-related Response Evaluation Criteria in Solid Tumors; iRECIST, immune 
RECIST; CR, complete response; PR, partial response; PD, progressive disease; SD, stable disease; CSI, cross-sectional imaging; TTB, 
total tumor burden; TMTB, total measured tumor burden; iUPD, unconfirmed progressive disease; iCPD, confirmed progressive disease.
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(complete response), iSD (stable disease) and iPR (partial 
response) but also unconfirmed PD (iUPD) and confirmed 
PD (iCPD) (see Table 2). These last two categories enable 
an improved characterization of atypical responses. Indeed, 
taking into account target lesions, iCR, iPR, and iSD are 
still possible after iUPD shows up, as long as iCPD is not 
identified. Furthermore, the demonstration of new lesions 
is classified as iUPD. To be assessed as iCPD, a further 
increase in size of previous new lesions (5 mm for the sum 
of target lesions or any increase in non-target lesions) 
or additional new lesions appearance is required at the 
subsequent CSI.
Of note, the RECIST work group suggest, once iUPD 
is identified, to perform the subsequent CSI evaluation 
between 4 and 8 weeks after, in order to allow the continuity 
of the treatment but also to enable a salvage therapy, if 
needed.
In a recent retrospective analysis Tazdait et al. (17) 
confirmed the usefulness of iRECIST criteria, showing 
11% of atypical responses, otherwise underestimated by the 
RECIST 1.1.
Radiological evaluation of adverse events
Immune-related adverse events (irAE) differ relevantly from 
adverse events of cytotoxic agents or targeted therapies. 
Radiologists should therefore be aware of the existence of 
these adverse events and of their radiological features in order 
to obtain an early diagnosis and a prompt treatment (22).
According to the literature, incidence is not negligible 
and varies between the 26% of anti-PD-1 drugs and 13.7% 
of anti-PD-L1 drugs (23), while pembrolizumab, a PD-1 
inhibitor, shows a lower rate of severe-to-life threatening 
adverse events in comparison with ipilimumab in advanced 
melanoma trial (24); ipilimumab (anti-CTLA4 drug) has 
been recently proposed in association with nivolumab (anti-
PD1) in NSCLC phase I trial, showing a percentage of 
adverse events of 17.4% and a treatment related deaths of 
1.2% (seven patients) (25).
A great number of organs and tissues can be involved 
in irAEs: skin and mucosae, bowels, lung, liver, pancreas, 
glands (thyroid, hypophysis, adrenal glands), kidney, eyes, 
central nervous system, blood, muscles and bones (25). 
The most common irAEs for which imaging is 
mandatory are colitis (7–17% incidence) and hypophysitis 
(4–11%) with the anti-CTLA-4 monoclonal antibody 
ipilimumab, and pneumonitis (3–6%) with anti-PD-1 
agents (13,23,26-28).
Colitis typically occurs after 6–7 weeks from the 
beginning of anti-CTLA-4 monoclonal antibody treatment 
and generally the colorectal involvement is diffuse (13,25). 
CT shows a fluid-filled colon, with thickened wall and 
increased mucosal enhancement, and mesenteric hyperemia. 
Sometimes the wall thickening can be segmental and 
superimposed to diverticulitis, the so called “segmental 
colitis associated with diverticulosis” (2).
Rarely, colitis can lead to perforation, easily identified by 
plain radiography or non-contrast CT (13).
Patients with anti-CTLA-4 monoclonal antibody 
hypophysitis presented with different non-specific 
symptoms, in particular headache and fatigue, and develop 
an anterior hypopituitarism persistent at follow-up. 
Magnetic resonance (MR) imaging demonstrate diffuse 
pituitary enlargement and/or heterogeneous pituitary 
enhancement at post-contrast images. Pituitary enlargement 
is generally reversible after glucocorticoid treatment.
Pneumonitis occur in 2–6% of Patients treated with anti-
PD-1/PDL-1 or CTLA-4 antibodies (25). According to 
Nishino et al. (29), median time to onset of pneumonitis is 
2.8 months (range, 9 days–19.2 months), but in some cases 
recurrent pneumonitis (“pneumonitis flare”) were diagnosed 
months after a successful steroid treatment of the irAEs, 
with or without retreatment with the immunotherapy 
previously discontinued.
CT scans generally demonstrate ground-glass opacities, 
consolidations, bronchiectasis,  interlobular septal 
thickening and intralobular lines (30). Sometimes CT shows 
crazy-paving pattern also, with diffuse or localised lung 
involvement (Figures 2-4). 
Four CT patterns have been recently identified in 
patients with nivolumab-induced pneumonitis (29): 
cryptogenic organizing pneumonia (COP) pattern in 65% 
of patients, nonspecific interstitial pneumonia pattern in 
15%, hypersensitivity pneumonitis pattern in 10%, and 
acute interstitial pneumonia (AIP)/acute respiratory distress 
syndrome (ARDS) in 10%.
Therefore, CT examinations show: (I) patchy ground-
glass opacities and consolidation in a subpleural, 
peribronchial or band pattern, sometimes accompanied by 
the reversed halo sign in the COP pattern; (II) bilateral 
ground-glass opacities with reticular opacities, traction 
bronchiectasis or bronchiolectasis and minimal or absent 
honey-combing in a basal distribution with subpleural 
sparing in the nonspecific interstitial pneumonia pattern; 
(III) centrilobular nodules and mosaic attenuation due to 
air trapping with an upper lobe-predominant distribution in 
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case of hypersensitivity pneumonitis; (IV) patchy bilateral 
ground-glass opacities with consolidation in the dependent 
lung in the AIP/ARDS pattern.
Patients on immune checkpoint inhibitors can also 
develop clinically silent new imaging findings, such as 
sarcoid-like distributed lymph nodes (bilateral hilar and 
mediastinal) (2). These nodes can’t be distinguished from 
nodal metastases, but in the setting of response at other 
sites their distribution resembles that of sarcoidosis. They 
might regress spontaneously, so treatment should not be 
discontinued.
Minor and rare irAEs are hepatitis and myositis. Patients 
with immune-related hepatitis are asymptomatic and 
present with abnormal laboratory test results. In these 
Patients ultrasound or CT can show periportal edema, mild 
hepatomegaly and periportal lymphadenopathy (2,13,25). 
However liver biopsy is necessary to make diagnosis of 
autoimmune hepatitis (31).
Contrast-enhanced CT can demonstrate new focal 
intramuscular enhancement, while PET/CT can show new 
intramuscular tracer uptake: these findings correlate with 
drug-related myositis (2).
Future perspectives and challenges
With the increasing role of immunotherapy in the treatment 
of lung cancer, diagnostic radiologists are asked to face 
increasingly difficult interpretative challenges: furthermore, 
in the next years the lung cancer clinical scenario will be 
even more complex. 
Diagnostic radiologists will be asked to interpret the 
radiological response of combined therapies (multiple 
targeted therapies mixed up with conventional chemo 
regimens) and their potential interactions with locoregional 
therapies (radiation and interventional oncology) and their 
potential synergic and abscopal effect (32-34). 
To overcome these difficulties, radiologists are asked to 
Figure 2 A 42-year-old female patient with NSCLC in treatment 
with nivolumab (anti-PD-1 monoclonal antibody). Axial chest CT 
reveals interlobular septal thickening with small patchy ground-
glass opacities in the lower lobes, in a crazy-paving configuration. 
NSCLC, non-small cell lung cancer.
Figure 3 A 64-year-old male patient with NSCLC in treatment 
with pembrolizumab (anti-PD-L1 monoclonal antibody). Axial 
chest CT shows pneumonitis characterized by peri-bronchial 
confluent parenchymal consolidation in the right lung in 
association with bilateral ground-glass opacities. NSCLC, non-
small cell lung cancer.
Figure 4 A 78-year-old male patient with NSCLC in treatment 
with nivolumab (anti-PD-1 monoclonal antibody). Axial chest CT 
demonstrates pneumonitis characterized by fibrosing reticulation, 
intralobular thickening and traction bronchiectasis, with large areas 
of honeycombing in the right lung. Pleural effusion is associated. 
In the left lung there is minimal subpleural interstitial reticulation. 
NSCLC, non-small cell lung cancer.
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have a deep knowledge of the different classification criteria 
in order to correctly interpret the outcome of clinical trials. 
Moreover, radiologists need to fully exploit the potential 
of the recent preliminary advances in the radiomics 
field (35-37), in order to better and deeply understand 
the clinical impact of the radiological responses after 
immunotherapy.
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